FDA flagged BPC-157 and roughly 19 other peptides for further evaluation, pausing compounding. Reclassification toward Category 1
When administered under medical supervision, patients typically receive treatments once or twice weekly, which can contribute to losing an additional 1-2 pounds per week when combined with proper semaglutide diet [6]
BPC-157 is locally acting - targets injury site through growth factor and fibroblast pathways, dosed in micrograms (250500 mcg), given twice daily
Clinical Evidence in Humans The topical evidence base is unusually robust for a research peptide: Facial aging study (71 women, 12 weeks): A GHK-Cu facial cream documented increased skin density and thickness, reduced laxity, improved clarity, and reduced fine lines and depth of wrinkles (PMID 26236730)
Sometimes treatment is reconstructive and other times men simply want to enhance their appearance or reduce signs of aging
Biochemical Profile: BPC-157 (Body Protection Compound 157) The third highly specialized element of this matrix is BPC-157, a synthetic pentadecapeptide (15-amino acid sequence) derived directly from a protective protein endemic to mammalian gastric fluid